As we enter 2026, the landscape of hepatology is being redefined by the rapid integration of non-invasive diagnostics. The Fibroscan Market forecast suggests a period of robust expansion, driven by the alarming rise in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Unlike the previous decade, where liver biopsies were the standard, the current year marks a turning...

The UK Fibroscan Market is instrumental in the ongoing efforts to address the rising burden of chronic liver disease. As the number of patients requiring long-term monitoring for conditions like NAFLD and viral hepatitis increases, the healthcare system faces the challenge of providing efficient and accurate diagnostic services. Fibroscan technology has become a vital part of the solution,...